Ir a las Transacciones
Salud

Choice Cancer Care has sold a majority interest to Cancer Treatment Centers America

The shareholder of Choice Cancer Care has sold a majority interest to Cancer Treatment Centers America. Financial details have not been disclosed.

Choice Cancer Care (CCC) is a QOPI certified medical and radiation oncology practice with six locations across North Texas. It is among the busiest practices in the country for brachytherapy, a prostate seed implant therapy.

Cancer Treatment Centers of America (CTCA) operates cancer treatment hospitals in Atlanta, Chicago, Philadelphia, Phoenix, and Tulsa and outpatient facilities in Chicago, Phoenix, and Scottsdale. With over 160 MDs, the company is highly regarded for its patient-centered philosophy, genomic and state-of-the-art technologies, wide array of precision treatment options, and comprehensive expertise across most cancer types.

Oaklins' team in Dallas contacted several strategic and private equity parties with a history of acquiring specialty practices. Typical metrics to value the business did not provide a profitable exit strategy. The team succeeded in cultivating good interest with a financially strong acquiror to expand its presence into North Texas and negotiated a highly profitable exit for the shareholder, including substantial cash, strong retention incentives, and continued ownership to monetize expansion efforts into underserved markets.

SERVICIO
M&A sell-side
PARTES

Contáctese con el equipo de la transacción

 Bryan  Livingston

Bryan Livingston

Socio Director

Dallas, Estados Unidos
Oaklins Capital Alliance

Transacciones Relacionadas

Global Media Santé has been acquired by SFP Expansion
Private Equity | Salud | TMT

Global Media Santé has been acquired by SFP Expansion

Global Media Santé’s CEO, Alain Trébucq, and Apax Partners have sold the company to SFP Expansion Group.

Ver más
Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Salud

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Ver más
Westminster Homecare has been acquired by Care at Home
Salud

Westminster Homecare has been acquired by Care at Home

The private shareholders of Westminster Homecare Ltd. have sold the company to Care at Home Services (South East) Ltd.

Ver más